Nykode Therapeutics AS (OSL:NYKD)

Market Cap	914.33M
Revenue (ttm)	104.04M
Net Income (ttm)	-441.04M
Shares Out	326.55M
EPS (ttm)	-1.36
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (35.71%)
Ex-Dividend Date	n/a

Volume	865,639
Average Volume	1,392,568
Open	2.878
Previous Close	2.752
Day's Range	2.732 - 2.878
52-Week Range	1.550 - 17.200
Beta	1.33
RSI	68.14
Earnings Date	Apr 25, 2025

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB1...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 136
• Stock Exchange: Oslo Børs
• Ticker Symbol: NYKD

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD